jnj-64530440
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 21, 2019 (NCT03890341)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03915886 | Phase 1 | Apr 15, 2019 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT03890341 | Phase 1 | Mar 21, 2019 | Johnson and Johnson |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 2 | 1 | 1 | 2019 |
| Janssen Pharmaceutica NV | For profit | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1